Are ace inhibitors vasodilators
Pro Research Analysisby 
Searched over 200M research papers
ACE Inhibitors as Vasodilators: A Comprehensive Analysis
Introduction to ACE Inhibitors and Vasodilation
Angiotensin-converting enzyme (ACE) inhibitors are a class of medications primarily used to treat conditions such as hypertension and heart failure. They function by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This inhibition leads to various physiological effects, including vasodilation. This article synthesizes research findings to explore the role of ACE inhibitors as vasodilators.
Mechanisms of Vasodilation by ACE Inhibitors
Enhancement of Bradykinin Effects
One of the primary mechanisms through which ACE inhibitors induce vasodilation is by potentiating the effects of bradykinin, a vasodilator peptide. Studies have shown that ACE inhibitors such as lisinopril, enalaprilat, and captopril significantly enhance bradykinin-induced relaxation in coronary arteries 23. This potentiation occurs because ACE inhibitors prevent the breakdown of bradykinin, thereby increasing its concentration and vasodilatory effects.
Nitric Oxide Production
ACE inhibitors also promote the release of nitric oxide (NO), a critical mediator of vasodilation. Research indicates that ACE inhibitors enhance endothelium-dependent vasodilation by increasing NO production. This effect is particularly evident in conditions like type 1 and type 2 diabetes, where endothelial function is often compromised 46. The increased NO production leads to improved vasodilation and better vascular health.
Reduction of Oxidant Stress
In hypertensive models, ACE inhibitors have been shown to reduce oxidant stress, which is a significant factor in endothelial dysfunction. By lowering oxidant stress levels, ACE inhibitors restore the vasodilator potency of endothelium-derived relaxing factors such as L-S-nitrosocysteine (L-SNC) and acetylcholine . This restoration contributes to the overall vasodilatory effect of ACE inhibitors.
Clinical Evidence of Vasodilation
Improvement in Endothelial Function
Clinical studies have demonstrated that ACE inhibitors improve endothelial function in various patient populations. For instance, in patients with coronary artery disease, quinapril significantly improved flow-mediated vasodilation (FMD) compared to other vasoactive agents . Similarly, in type 1 diabetic patients with microalbuminuria, both captopril and enalapril normalized endothelium-dependent vasodilation .
Vasodilatory Effects in Heart Failure
In patients with chronic heart failure (CHF), ACE inhibitors have been shown to enhance vasodilation. Studies involving endothelin-converting enzyme (ECE) inhibitors and endothelin ETA receptor antagonists indicate that these agents can further increase forearm blood flow in CHF patients already treated with ACE inhibitors . This suggests that ACE inhibitors play a crucial role in managing vascular tone in heart failure.
Conclusion
ACE inhibitors are effective vasodilators, primarily through mechanisms involving the potentiation of bradykinin effects, increased nitric oxide production, and reduction of oxidant stress. Clinical evidence supports their role in improving endothelial function and enhancing vasodilation in various cardiovascular conditions. These findings underscore the importance of ACE inhibitors in the management of hypertension, heart failure, and other related disorders.
Sources and full results
Most relevant research papers on this topic